[if gte mso 9] > < xml >
<!-[if gte mso 10] >
Avonex ® pen is now available in Spain for treatmentof multiple sclerosis
-Avonex Pen ® is the first IM autoinyector for the treatment of sclerosisMultiple, weekly to improve the comfort of therapy and therefore its qualitylife
Madrid, June 2012. – Avonex Pen ®, the new format of thedrug for the treatment of the sclerosis multiple Avonex ® (interferon)(beta-1a), is already available in Spain Avonex Pen ® is the first autoinyectorintramuscular weekly, disposable and easy to apply, which improves thecomfort of therapy this treatment, and consequently, their adherenceand their quality of life.
Avonex ® (interferon beta-1a), Biogen Idec, is one of themost prescribed treatments around the world for the type of EMSender-Recidivante (RRMS), with more than 141.694 patients treated. It hasproven to be effective in decreasing the inability, of the rate ofthe development of identified brain lesions and clinical recurrence byMagnetic resonance imaging (MRI).
the new Pen Avonex ® device, is designed toalleviate the concerns associated with the administration of Avonex ®, as theanxiety by injection, needle phobia or the need for coordinationphysically the injection, making the completely autonomous patient.
Avonex Pen ® integrates the pre-loaded syringe system ofAvonex ® with a 16 mm needle,specifically created to be shorter than the needle of the treatmenttraditional.
Avonex ® Pen, thus additional includes: protective screen of the nozzle,that hides the needle before the injection, automatic needle insertion andadministration of medication, as well as diameter and length designed forIn addition, stabilizing treatment during the procedure of injection.It incorporates a safety lock that helps to avoid errors, and a windowdisplay which confirms the full administration of the drug.
the adoption of Avonex Pen by the European Union is based, inpart, on the results of the study Phillips an open studymulticenter, phase III, which assessed their safety and efficacy. They includedpatients with MS who had used the syringe pre-loaded with Avonex ®for at least 12 weeks prior to inclusion in the study. We evaluated theefficacy of Avonex ® Pen through objective and subjective analysis of thekey aspects of its use by patients. In the study, the rate ofglobal success of patients using Avonex ® Pen was 89%. In thissame research, 94% of patients expressed their preference forAvonex ® Pen with respect to the Avonex ® pre-loaded syringe.
About Biogen Idec
Biogen Idec creates new standards of care in areastherapeutic with unmet medical needs. Founded in 1978, BiogenIDEC is a world leader in the discovery, development, manufacturing andcommercialization of innovative therapies for unmet needsin the areas of Immunology, Neurology and hemophilia.
